Boothbay Fund Management LLC Grows Stock Holdings in Pharvaris N.V. $PHVS

Boothbay Fund Management LLC raised its holdings in shares of Pharvaris N.V. (NASDAQ:PHVS) by 735.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,181 shares of the company’s stock after acquiring an additional 118,994 shares during the quarter. Boothbay Fund Management LLC’s holdings in Pharvaris were worth $3,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc raised its stake in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period. Amundi lifted its holdings in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, HighVista Strategies LLC lifted its holdings in Pharvaris by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after purchasing an additional 971 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Oppenheimer lifted their target price on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Royal Bank Of Canada assumed coverage on shares of Pharvaris in a research note on Monday, March 9th. They set an “outperform” rating and a $52.00 price objective for the company. Finally, Leerink Partners set a $38.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and a consensus target price of $41.70.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $26.93 on Tuesday. The stock’s 50-day simple moving average is $26.73 and its two-hundred day simple moving average is $25.02. Pharvaris N.V. has a twelve month low of $11.51 and a twelve month high of $29.80.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.